Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281102 | 0.83 | CA1 (0.46) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL9635656 | 0.80 | KMT2A (0.39) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL8786752 | 0.79 | CA12 (0.39) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL30281403 | 0.79 | CA12 (0.49) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL23990414 | 0.78 | ALDH1A1 (0.33) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL23989449 | 0.78 | PARP10 (0.35) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL30281212 | 0.75 | KMT2A (0.38) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL23990406 | 0.74 | CA12 (0.36) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL23989451 | 0.74 | CA12 (0.36) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL30999032 | 0.74 | ALDH1A1 (0.31) | KMT2ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207206-B2 | (S,R)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent | ONCONOX APS (DK) | 2012-06-26 | — | — | US | disclosed |
| EP-2144904-B1 | (S,R)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | GANIAL IMMUNOTHERAPEUTICS INC (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100305176-A1 | (S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | GANIAL IMMUNOTERAPEUTICS INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2144904-A1 | (S,R)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | Ganial Immunotherapeutics Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008138516-A1 | (S,R)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | GANIAL IMMUNOTERAPEUTICS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305176-A1 | (S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | MAPK7, CASP7, ANXA7 | KMT2A 4556/4885CA12 2627/4885CA1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.